Authors
Loading...
Cost-effectiveness analysis evaluates expanded recombinant zoster vaccination for the elderly, suggesting potential healthcare savings.
Ku et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: